Document is current
Any future updates will be listed below
-
Authors
Eleftheriadou, Aikaterini https://orcid.org/0000-0002-7290-8523
Spallone, Vincenza https://orcid.org/0000-0002-8905-216X
Tahrani, Abd A. https://orcid.org/0000-0001-9037-1937
Alam, Uazman https://orcid.org/0000-0002-3190-1122
- License Information
-
More Information
Article History
Received: 1 March 2024
Accepted: 10 June 2024
First Online: 9 August 2024
Authors’ relationships and activities
: VS has received consultant honoraria from Angelini, AWP, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Servier, Schwarz Pharma, TrigoCare and Wörwag Pharma, speaker honoraria from Boehringer Ingelheim, Eli Lilly, Impeto Medical, Laborest, Nevro Medical, Pfizer, Sanofi, Theras Lifetech, Viatris and Wörwag Pharma, and research funding from Biocure and Boehringer Ingelheim. AAT is currently an employee and shareholder of Novo Nordisk. Novo Nordisk had no role in this project and the views represented are those of the author and not Novo Nordisk. UA has received honoraria from Procter & Gamble, Viatris, Eli Lilly, Grunenthal and Sanofi for educational meetings and has received investigator-led funding from Procter & Gamble. UA has received sponsorship for travel to an international conference from Daiichi Sankyo. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: All authors contributed to drafting the article and critically reviewing it for important intellectual content. All authors approved the final version to be published.
